AIMS: Depression is the most frequent comorbidity reported among patients with rheumatoid arthritis (RA). Comorbid depression negatively impacts RA patients' health-related quality-of-life, physical function, mental function, mortality, and experience of pain and symptom severity. The objective of this study was to assess healthcare utilization, expenditures, and work productivity among patients with RA with or without depression. MATERIALS AND METHODS: Data from adult patients who had at least two visits each related to RA and depression over a 1-year period were extracted from the Truven Health MarketScan research databases. Outcomes comprised healthcare resource utilization, work productivity loss, and direct healthcare costs comparing patients with RA with depression (n = 3,478) vs patients with RA without depression (n = 43,222). RESULTS: Patients with RA and depression had a significantly greater relative risk of hospitalization and number of all-cause and RA-related hospitalizations, utilization of emergency services, days spent in the hospital, physician visits, and RA-related surgeries compared with RA patients without depression. Patients with RA and depression had a higher risk of and experienced more events and days of short-term disability compared with patients without depression. The incremental adjusted annual all-cause and RA-related direct costs were $8,488 (95% CI = $6,793-$10,223) and $578 (95% CI = -$98-$1,243), respectively, when comparing patients with RA and depression vs RA only. LIMITATIONS: The current analysis is subject to the known limitations of retrospective studies based on administrative claims data. CONCLUSIONS: This study suggested increased healthcare utilization, work productivity loss, and economic burden among RA patients due to comorbid depression. These findings emphasize the importance of managing depression and including depression as a factor when devising treatment algorithms for patients with RA.
AIMS: Depression is the most frequent comorbidity reported among patients with rheumatoid arthritis (RA). Comorbid depression negatively impacts RApatients' health-related quality-of-life, physical function, mental function, mortality, and experience of pain and symptom severity. The objective of this study was to assess healthcare utilization, expenditures, and work productivity among patients with RA with or without depression. MATERIALS AND METHODS: Data from adult patients who had at least two visits each related to RA and depression over a 1-year period were extracted from the Truven Health MarketScan research databases. Outcomes comprised healthcare resource utilization, work productivity loss, and direct healthcare costs comparing patients with RA with depression (n = 3,478) vs patients with RA without depression (n = 43,222). RESULTS:Patients with RA and depression had a significantly greater relative risk of hospitalization and number of all-cause and RA-related hospitalizations, utilization of emergency services, days spent in the hospital, physician visits, and RA-related surgeries compared with RApatients without depression. Patients with RA and depression had a higher risk of and experienced more events and days of short-term disability compared with patients without depression. The incremental adjusted annual all-cause and RA-related direct costs were $8,488 (95% CI = $6,793-$10,223) and $578 (95% CI = -$98-$1,243), respectively, when comparing patients with RA and depression vs RA only. LIMITATIONS: The current analysis is subject to the known limitations of retrospective studies based on administrative claims data. CONCLUSIONS: This study suggested increased healthcare utilization, work productivity loss, and economic burden among RApatients due to comorbid depression. These findings emphasize the importance of managing depression and including depression as a factor when devising treatment algorithms for patients with RA.
Authors: Phuong Bich Tran; Joseph Kazibwe; Georgios F Nikolaidis; Ismo Linnosmaa; Mieke Rijken; Josefien van Olmen Journal: BMC Med Date: 2022-07-19 Impact factor: 11.150
Authors: Carol A Hitchon; Randy Walld; Christine A Peschken; Charles N Bernstein; James M Bolton; Renée El-Gabalawy; John D Fisk; Alan Katz; Lisa M Lix; James Marriott; Scott B Patten; Jitender Sareen; Alexander Singer; Ruth Ann Marrie Journal: Arthritis Care Res (Hoboken) Date: 2021-01 Impact factor: 4.794
Authors: Ana Isabel González-González; Robin Brünn; Julia Nothacker; Christine Schwarz; Edris Nury; Truc Sophia Dinh; Maria-Sophie Brueckle; Mirjam Dieckelmann; Beate Sigrid Müller; Marjan van den Akker Journal: Int J Environ Res Public Health Date: 2021-12-21 Impact factor: 3.390
Authors: Arkady T Manning-Bennett; Ashley M Hopkins; Michael J Sorich; Susanna M Proudman; David J R Foster; Ahmad Y Abuhelwa; Michael D Wiese Journal: Ther Adv Musculoskelet Dis Date: 2022-07-22 Impact factor: 3.625